At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
In Brief
A Phase 3 clinical trial evaluating Rituximab, Cyclophosphamide, and 4 other interventions for Non-Hodgkin Lymphoma. Completed, enrolled 139 participants across 13 sites in 3 countries.
Detailed Summary
This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).
Study Details
Timeline
Interventions
Rituximab SC 1400 mg
Cyclophosphamide will be administered as per standard local practice.
Doxorubicin will be administered as per standard local practice.
Vincristine will be administered as per standard local practice.
Prednisone will be administered as per standard local practice.
Fludarabine will be administered as per standard local practice.